Abstract
A series of tylophora alkaloids and their derivatives (1–38) were synthesized and systematically bioassayed for their anti-HIV activity for the first time. The results revealed that most of these alkaloids possess good HIV inhibitory effect. Especially, compounds 1, 4 and 25 displayed low nanomolar levels of anti-HIV activity (inhibitory effect at 50 nM: 1: 71%; 4: 60%; 25: 64%), which is about similar to that of the first HIV inhibitor AZT (inhibitory effect at 50 nM: 70%) and slightly lower than that of the first HIV integrase inhibitor MK-0518 (inhibitory effect at 50 nM: 82%). Present studies provide fundamental support for the development of tylophora alkaloids as novel HIV inhibitors.
Keywords: AIDS, anti-HIV activity, HIV inhibitor, natural product, structure-activity relationship, tylophora alkaloids.
Letters in Drug Design & Discovery
Title:First Discovery of Tylophora Alkaloids as HIV Inhibitors
Volume: 12 Issue: 4
Author(s): Ziwen Wang, Mingxiao Wang, Lei Wang, Xue Yao, Yue Li, Juan Tan, Wentao Qiao, Yunqi Geng, Yuxiu Liu and Qingmin Wang
Affiliation:
Keywords: AIDS, anti-HIV activity, HIV inhibitor, natural product, structure-activity relationship, tylophora alkaloids.
Abstract: A series of tylophora alkaloids and their derivatives (1–38) were synthesized and systematically bioassayed for their anti-HIV activity for the first time. The results revealed that most of these alkaloids possess good HIV inhibitory effect. Especially, compounds 1, 4 and 25 displayed low nanomolar levels of anti-HIV activity (inhibitory effect at 50 nM: 1: 71%; 4: 60%; 25: 64%), which is about similar to that of the first HIV inhibitor AZT (inhibitory effect at 50 nM: 70%) and slightly lower than that of the first HIV integrase inhibitor MK-0518 (inhibitory effect at 50 nM: 82%). Present studies provide fundamental support for the development of tylophora alkaloids as novel HIV inhibitors.
Export Options
About this article
Cite this article as:
Wang Ziwen, Wang Mingxiao, Wang Lei, Yao Xue, Li Yue, Tan Juan, Qiao Wentao, Geng Yunqi, Liu Yuxiu and Wang Qingmin, First Discovery of Tylophora Alkaloids as HIV Inhibitors, Letters in Drug Design & Discovery 2015; 12 (4) . https://dx.doi.org/10.2174/1570180811666141009235124
DOI https://dx.doi.org/10.2174/1570180811666141009235124 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Vitamin D Intake and Obesity in Occupational Asthma Patients and the Need for Supplementation
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Chaos and Gene expression: A Theoretical Approach
Recent Patents on Biomedical Engineering (Discontinued) Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Calculation of Molecular Features with Apparent Impact on Both Activity of Mutagens and Activity of Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Computational Drug Design Targeting Protein-Protein Interactions
Current Pharmaceutical Design Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome
Current Molecular Medicine Inhibitors of the Chemokine Receptor CXCR4: Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis
Letters in Drug Design & Discovery Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer
Current Cancer Drug Targets Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form
Current Pharmaceutical Analysis Tamoxifen: Is it Safe? Comparison of Activation and Detoxication Mechanisms in Rodents and in Humans
Current Drug Metabolism Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Meet our Editorial Board Member
Current Cancer Therapy Reviews